Biofluid biomarkers for Alzheimer's disease

Sensen Wang; Sitan Xie; Qinpin Zheng; Zhihui Zhang; Tian Wang; Guirong Zhang

doi:10.3389/fnagi.2024.1380237

Biofluid biomarkers for Alzheimer's disease

Front Aging Neurosci. 2024 Apr 10:16:1380237. doi: 10.3389/fnagi.2024.1380237. eCollection 2024.

Authors

Sensen Wang^#^{1

2}, Sitan Xie^#¹, Qinpin Zheng^{1

2}, Zhihui Zhang¹, Tian Wang², Guirong Zhang^{1

2}

Affiliations

¹ Shandong Yinfeng Academy of Life Science, Jinan, Shandong, China.
² School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, Shandong, China.

^# Contributed equally.

Abstract

Alzheimer's disease (AD) is a multifactorial neurodegenerative disease, with a complex pathogenesis and an irreversible course. Therefore, the early diagnosis of AD is particularly important for the intervention, prevention, and treatment of the disease. Based on the different pathophysiological mechanisms of AD, the research progress of biofluid biomarkers are classified and reviewed. In the end, the challenges and perspectives of future research are proposed.

Keywords: Alzheimer’s disease; biofluid; biomarkers; diagnosis; neurodegenerative diseases.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Shandong Yinfeng Academy of Life Science.